M&A Deal Summary

Sangamo Therapeutics Acquires TxCell S.A.

On July 23, 2018, Sangamo Therapeutics acquired life science company TxCell S.A. for 72M EUR

Acquisition Highlights
  • This is Sangamo Therapeutics’ 4th transaction in the Life Science sector.
  • This is Sangamo Therapeutics’ 0th largest (disclosed) transaction.
  • This is Sangamo Therapeutics’ 1st transaction in France.

M&A Deal Summary
Date 2018-07-23
Target TxCell S.A.
Sector Life Science
Buyer(s) Sangamo Therapeutics
Deal Type Add-on Acquisition
Deal Value 72M EUR

Target

TxCell S.A.

Valbonne, France
TxCell S.A. is a biotechnology company that develops platforms for innovative, personalized T cell immunotherapies for the treatment of severe inflammatory and autoimmune diseases with high unmet medical need. TxCell is targeting transplantation as well as a range of autoimmune diseases (both T-cell and B-cell-mediated), such as multiple sclerosis, rheumatoid arthritis, inflammatory bowel diseases or inflammatory skin diseases.

Search 200,291 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Sangamo Therapeutics

Richmond, California, United States
Category Company
Founded 1995
Sector Life Science
Employees405
Revenue 176M USD (2023)
DESCRIPTION

Sangamo Therapeutics is a clinical stage biopharmaceutical company, focuses on the research, development, and commercialization of zinc finger DNA-binding proteins (ZFPs) for gene regulation and gene modification in the United States. Its ZFPs could be engineered to make ZFP nucleases (ZFNs) proteins, which could be used to modify DNA sequences in various ways; and ZFP transcription factors (ZFP TFs) proteins that could be used to turn genes on or off. The company?s principal ZFP therapeutic is SB-728-T, a ZFN-modified autologous T-cell product, which is in Phase II and Phase I/II clinical trials for the treatment of human immunodeficiency virus and acquired immunodeficiency syndrome. Sangamo Therapeutics was founded in 1995 and is based in Richmond, California.

DEAL STATS #
Overall 4 of 4
Sector (Life Science) 4 of 4
Type (Add-on Acquisition) 3 of 3
Country (France) 1 of 1
Year (2018) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2013-08-26 Ceregene

San Diego, California, United States

Using gene therapy delivery systems, Ceregene’s primary focus is the discovery and development of novel growth factor therapeutics for the treatment of neurological disorders. Ceregene has completed Phase I clinical trials in Alzheimer’s and Parkinson’s disease, and is currently conducting a double blind Phase II trial in Parkinson’s disease.

Buy -
Mergr

Product

Company

Legal